Dr. Patrick Mann, until recently in charge of the lengthy molecular oncology policies at Novitas MAC, is now at the NGS MAC. See his Linked In here:
https://www.linkedin.com/in/patrick-mann-md-0657a2153/
Dr. Mann did his pathology residency at Univ Colorado, and a postdoc in molecular pathology at Washington University - St Louis. Recently he has been at Variantyx (2020-2021), Novitas (2021-2025), and NGS MAC (since April 2025).
Changing Geographies
At Novitas, Dr Mann managed policies for the purple states and Florida (a related MAC with a different name). At NGS MAC, they have the navy-blue states (MN WI IL and NY-New England).
Hypothetical
I have been wondering if the NGS MAC states would join the MOLDX system, since in this year's Gapfill process, the NGS MAC adopted or was given all the prices and all the rationales exactly the same as used by the MolDx consortium.
NGS MAC: A Few Big Labs and NCDs
Historically, NGS MAC pays claims for Cologuard (Wisconsin, under an NCD) and Tempus and Foundation Medicine (in Chicago and in Boston, and now under NCDs for FDA CDx tests). Outside of NCD-driven molecular claims, NGS MAC has generally paid relatively few molecular claims, at least in Part B data (which excludes large hospitals like Mayo and MGH in this geography).
